Marwan G. Fakih, MD

Marwan G. Fakih, MD, is a professor in the Department of Medical Oncology & Therapeutics Research, associate director of Clinical Sciences, medical director of Briskin Center for Clinical Research, division chief of GI Medical Oncology, and co-director of the Gastrointestinal Cancer Program at City of Hope.

Articles

SUNLIGHT Regimen in Third-Line mCRC: Insights on Treatment Management and Practical Nuances

July 9th 2025

Panelists discuss how they modify dosing schedules for TAS-102 (trifluridine/tipiracil), with some preferring every-other-week dosing instead of the standard 2-weeks-on schedule to reduce neutropenia and improve tolerability.

Role of Regorafenib in Third-Line mCRC: Expert Insights on Treatment Strategies and Management Nuances

July 9th 2025

Panelists discuss how clinical trials remain the preferred option in third-line treatment, while acknowledging that regorafenib may benefit from dose reduction strategies and potential combination with immunotherapy in select patients.

A Review of the Treatment Options in Third-Line mCRC and Therapy Sequencing Strategies

June 30th 2025

Panelists discuss how 3 drugs (regorafenib, TAS-102, and fruquintinib) offer modest but meaningful survival benefits in treatment-refractory colorectal cancer, with TAS-102 plus bevacizumab being the preferred combination when tolerated.

The Role of ctDNA in the Management of mCRC

June 30th 2025

Panelists discuss how circulating tumor DNA testing serves as the best prognostic technology available, particularly useful for identifying high-risk stage II patients who would benefit from adjuvant therapy, though surveillance strategies for positive results remain unclear.

CheckMate 8HW Expanded Analysis at ASCO 2025: Implications for Treatment Decisions in MSI-H mCRC

June 23rd 2025

Panelists discuss how doublet immunotherapy with ipilimumab and nivolumab provides superior outcomes compared to single-agent PD-1 therapy or chemotherapy in microsatellite instability-high colorectal cancer, supporting the “hit hard, hit early” approach.

Expert Insights: BREAKWATER Survival Data Update From ASCO 2025

June 23rd 2025

Panelists discuss how the BREAKWATER trial demonstrates that upfront treatment with encorafenib plus cetuximab significantly improves outcomes in BRAF V600E-mutated colorectal cancer, turning a historically poor prognostic marker into a targetable opportunity.

DPD Testing and Medication Dosage Adjustments in mCRC Patients

June 16th 2025

Panelists discuss how dihydropyrimidine dehydrogenase testing remains controversial with institutions debating whether to implement universal pharmacogenomic testing given the challenges of standardization, genotype-phenotype correlation, and low incidence of severe deficiency.

The Importance of Biomarker Testing in mCRC

June 16th 2025

John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS; and Katrina S. Pedersen, MD, discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for microsatellite instability-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.

Dr Fakih on the FDA Approval of Retifanlimab for Advanced Anal Cancer

May 20th 2025

Marwan Fakih, MD, discusses the clinical relevance of the FDA’s approval of retifanlimab for patients with squamous cell carcinoma of the anal canal.

Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC

March 18th 2025

Marwan Fakih, MD, discusses the advancement of botensilimab/balstilimab–based combination therapies in microsatellite-stable colorectal cancer.

Dr Fakih on the Importance of Genetic Testing in KRAS G12C–Mutant mCRC

March 10th 2025

Marwan G. Fakih, MD, emphasizes the need for next-generation sequencing in colorectal cancer to inform treatment sequencing.

FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD

March 3rd 2025

Marwan G. Fakih, MD discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial, and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.

Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC

February 7th 2025

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab for adult patients with KRAS G12C–mutated metastatic colorectal cancer.

Dr Fakih on Responses With Botensilimab Plus Balstilimab in MSS CRC

February 6th 2025

Marwan G. Fakih, MD, discusses response rates with botensilimab plus balstilimab in patients with microsatellite-stable colorectal cancer.

Dr Fakih on OS Data for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

June 27th 2024

Marwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

April 11th 2024

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Unmet Needs Surrounding mCRC Treatment

April 11th 2024

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

Data Surrounding Treatment for MSI-high Patients from ASCO 2024

April 4th 2024

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Real-World Data Surrounding Sequencing Strategies for Refractory mCRC

April 4th 2024

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis

March 28th 2024

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.